THE CHROMOSOME | Clinical Content Series
Sex Hormone Binding Globulin Disorders
Back to Case Studies ArchiveCase Study
She was 33 years old and had been told her hormones were normal. She had been told this by two gynaecologists and one endocrinologist across three years of increasingly frustrating clinical encounters in which she had presented with symptoms that were entirely real, entirely consistent, and entirely unexplained by the test results her physicians were returning to her. She had irregular periods. She had significant facial hair along her jawline and upper lip. She had acne across her chin and neck that had not responded to two courses of antibiotics and one course of isotretinoin. She had gained 16 kilograms across four years despite what she described, with justified exasperation, as eating less than anyone she knew.
Her testosterone on every panel that had been ordered was within the normal female range. Her oestrogen was normal. Her LH and FSH were within range. By the hormonal criteria her physicians were applying she was hormonally unremarkable, and therefore her symptoms were unexplained and her weight gain was attributed to her diet.
When she came to me I ordered one additional measurement that none of her previous physicians had included in their panels. Her sex hormone binding globulin was 12 nanomoles per litre. The lower limit of the normal female range is 32. Her SHBG was less than half the minimum level required for normal hormonal regulation, and that single finding explained everything that three years of normal hormone panels had failed to explain.
Sex hormone binding globulin is a protein produced by the liver that binds to sex hormones, primarily testosterone and oestrogen, in the bloodstream and regulates their biological activity. The total hormone measured on a standard panel includes both the bound, biologically inactive fraction and the tiny free fraction that actually enters cells and exerts hormonal effects. When SHBG is severely low, the bound fraction shrinks, releasing a disproportionately large free fraction of whatever hormones are circulating. Her total testosterone was normal. But with SHBG at 12 instead of 32, the free testosterone, the fraction acting on her androgen receptors, was more than double what it should have been. She had the hormonal equivalent of high testosterone without a single testosterone measurement confirming it, because every panel her physicians had ordered had measured the total without calculating the free.
This is one of the most important diagnostic blind spots in Pakistani hormonal medicine. The free hormone is the biologically active hormone. The total hormone is the pool from which the free fraction is drawn. Measuring total without SHBG tells you how large the pool is without telling you how much of it is actually available to act on the body's tissues, and in patients with low SHBG, the available fraction is dramatically and disproportionately elevated regardless of what the total measurement shows.
Her low SHBG had a clear metabolic origin. Her fasting insulin was significantly elevated, hyperinsulinaemia is one of the most potent suppressors of hepatic SHBG production in human physiology. The liver produces SHBG at a rate that is directly and powerfully inhibited by insulin, meaning that every Pakistani patient with insulin resistance and compensatory hyperinsulinaemia is producing less SHBG than their hormonal balance requires, releasing more free sex hormone than their tissues were designed to handle, and experiencing the consequences of hormone excess without a single hormone measurement reflecting the elevation. Her visceral fat was accumulating the inflammatory cytokines that further suppressed hepatic SHBG synthesis. Her thyroid function, while technically within range, showed the subclinical conversion impairment that reduces SHBG production independently of insulin.
The FTO gene's influence on SHBG in Pakistani patients operates primarily through its promotion of hyperinsulinaemia and visceral fat accumulation, the two most powerful suppressors of hepatic SHBG synthesis in the clinical literature. Pakistani patients with the FTO associated metabolic profile develop the insulin levels and visceral fat burden that suppress SHBG at lower degrees of overall obesity than Western populations, meaning that SHBG disorders manifest earlier, more severely, and with more profound hormonal consequences in the Pakistani population than global clinical statistics would suggest. I measure SHBG in every Pakistani patient I evaluate hormonally, because without it, the free hormone fractions that actually govern biological activity are invisible, and the hormonal picture I am building is systematically incomplete.
For Pakistani women, low SHBG in the context of hyperinsulinaemia creates the androgen excess that drives PCOS, facial hair, acne, menstrual irregularity, and the visceral fat accumulation that further suppresses SHBG in a self reinforcing cycle. For Pakistani men, low SHBG in the context of visceral obesity creates a paradoxical situation in which total testosterone may appear adequate while free testosterone is either inappropriately elevated, driving the androgenic consequences of excess, or appropriately low, creating the hypogonadal consequences of deficiency, depending on the direction of the hormonal imbalance and the degree of aromatase driven testosterone to oestrogen conversion.
We addressed the root cause of her SHBG suppression. We treated her insulin resistance, the primary driver of hepatic SHBG suppression. We reduced her visceral fat, removing the inflammatory cytokine environment that was compounding the insulin mediated SHBG suppression. We optimised her thyroid conversion, supporting the hepatic function required for adequate SHBG synthesis. We addressed her oestrogen progesterone balance, because progesterone supports SHBG production while oestrogen dominance impairs it.
Eleven months later her SHBG had risen to 38 nanomoles per litre, within the normal range for the first time in years. Her free testosterone had normalised. Her facial hair growth had slowed substantially. Her acne had resolved. Her periods had regularised. She had lost 14 kilograms. And her total testosterone on every panel remained exactly what it had always been, normal, because the problem had never been her total testosterone. The problem had been the SHBG that had been allowing too much of it to act freely on her tissues.
Three years of symptoms. Three years of normal panels. One additional measurement. Everything explained.
FAQs
Sex hormone binding globulin is a liver produced protein that binds to testosterone and oestrogen in the bloodstream, regulating how much of each hormone is biologically active at any given moment. Only the unbound, free fraction of a sex hormone can enter cells and exert hormonal effects, meaning that SHBG is the primary gatekeeper of hormonal bioavailability. Despite its central importance to hormonal regulation, SHBG is almost never included in standard Pakistani hormonal panels, because Pakistani clinical practice measures total hormone levels without accounting for the binding protein that determines how much of that total is actually doing anything. The result is a systematic diagnostic blind spot in which significant hormonal disorders, androgen excess driving PCOS and hirsutism, relative androgen deficiency driving metabolic deterioration, are invisible to the physician ordering the panel and unexplained to the patient experiencing the consequences.
Insulin directly inhibits hepatic SHBG synthesis, the liver produces less SHBG in the presence of elevated insulin, releasing a disproportionately large free fraction of circulating sex hormones. In Pakistani patients with hyperinsulinaemia, which is present in the majority of those with significant visceral obesity, this insulin mediated SHBG suppression creates a state of functional androgen excess in women and hormonal imbalance in men that standard hormonal panels consistently fail to identify because they measure total rather than free hormones. The clinical consequences, acne, facial hair, menstrual irregularity, PCOS symptoms in women, and paradoxical hormonal imbalances in men, are attributed to unexplained hormonal disorder when they are in fact the entirely predictable consequence of insulin driven SHBG suppression operating invisibly beneath a normal total hormone panel.
The FTO gene at Chromosome 16q12.2 promotes visceral fat accumulation and hyperinsulinaemia in Pakistani patients at lower body weight thresholds than Western populations, and both visceral fat accumulation and hyperinsulinaemia are potent suppressors of hepatic SHBG production. The inflammatory cytokines released by visceral fat directly impair hepatic SHBG synthesis independently of insulin, compounding the insulin mediated suppression with an additional inflammatory mechanism. In Pakistani patients with the FTO associated metabolic profile, SHBG suppression develops earlier, more severely, and with more profound hormonal consequences than in Western populations at equivalent degrees of obesity. Dr. Zaar measures SHBG as a standard component of every hormonal assessment in Pakistani patients, because the FTO associated predisposition to SHBG suppression means that free hormone disorders are substantially more prevalent in this population than total hormone measurements alone would ever reveal.
In Pakistani women with hyperinsulinaemia and low SHBG, the combination of insulin driven ovarian androgen overproduction and SHBG mediated amplification of free androgen bioavailability creates an androgenic environment that produces PCOS symptoms at total testosterone levels that fall within the normal female range. The ovaries, stimulated by excess insulin, produce more testosterone than they should. The liver, suppressed by excess insulin, produces less SHBG than it should. The result is a free testosterone level that is disproportionately elevated relative to the total, producing the acne, facial hair, menstrual irregularity, and anovulation of androgen excess without a single testosterone measurement confirming it. Pakistani women with this presentation are told their testosterone is normal and their symptoms are unexplained, when the explanation has always been present in the SHBG that was never measured.
In Pakistani men with visceral obesity and hyperinsulinaemia, low SHBG creates a more complex hormonal picture than in women because the direction of the sex hormone imbalance depends on the relative contributions of androgen deficiency and aromatase driven oestrogen excess. When visceral fat aromatises testosterone to oestrogen more rapidly than testosterone is produced, which occurs in men with significant visceral adiposity and declining testosterone, low SHBG amplifies the free oestrogen excess that suppresses the hypothalamic LH signal and deepens testosterone deficiency. When testosterone is relatively preserved, low SHBG may amplify free testosterone bioavailability, creating a paradoxical androgenic environment in an apparently hypogonadal man. Understanding which pattern is operating requires measuring SHBG alongside total testosterone, free testosterone, and oestradiol simultaneously, which THE CHROMOSOME protocol does as standard in every male hormonal assessment.
SHBG levels are directly and substantially responsive to the correction of the metabolic drivers suppressing them, making SHBG normalisation an achievable clinical goal in Pakistani patients who receive comprehensive metabolic treatment. Insulin resistance reversal is the single most powerful intervention for SHBG restoration, reducing the primary hepatic suppression signal that has been preventing adequate SHBG synthesis. Visceral fat reduction removes the inflammatory cytokine contribution to SHBG suppression. Thyroid function optimisation supports the hepatic metabolic environment required for adequate SHBG production. Oestrogen progesterone balance restoration supports SHBG synthesis through progesterone's direct hepatic stimulatory effect on SHBG production. In Dr. Zaar's clinical experience, SHBG levels in Pakistani patients treated comprehensively through THE CHROMOSOME protocol normalise progressively over six to twelve months, with corresponding resolution of the hormonal consequences that SHBG suppression had been producing.
Low SHBG is an independent predictor of cardiovascular disease risk in both men and women, a relationship that reflects its role as a marker of the insulin resistance, visceral obesity, and metabolic syndrome that drive cardiovascular pathology. In Pakistani patients, where cardiovascular disease occurs earlier, more severely, and at lower degrees of traditional risk factor burden than in Western populations, low SHBG represents a cardiovascular risk signal whose significance extends beyond its hormonal consequences. The free androgen excess that low SHBG produces in Pakistani women is independently associated with endothelial dysfunction, dyslipidaemia, and the inflammatory vascular environment that underlies premature coronary artery disease. In Pakistani men, the oestrogen testosterone imbalance amplified by low SHBG contributes to the adverse lipid profile, elevated inflammatory markers, and impaired cardiac function associated with hypogonadism. THE CHROMOSOME protocol treats SHBG normalisation as a cardiovascular intervention as much as a hormonal one.
Free testosterone, the biologically active fraction not bound to SHBG or albumin, is the clinically relevant measurement for assessing androgenic activity in Pakistani patients with SHBG disorders. In women with low SHBG, free testosterone may be disproportionately elevated while total testosterone remains normal, identifying androgen excess that total measurement conceals and explaining the PCOS symptoms, hirsutism, and acne that a normal total testosterone panel cannot account for. In men with low SHBG, free testosterone may be disproportionately low while total testosterone appears borderline adequate, identifying functional hypogonadism that total measurement underestimates and explaining the fatigue, muscle loss, and metabolic deterioration that a borderline total testosterone dismisses. Calculating free testosterone from total testosterone and SHBG, or measuring it directly, transforms the clinical picture from unexplained to precisely characterised and from unaddressed to specifically treatable. This calculation costs nothing additional to the hormonal panel. It requires only that SHBG be included, and that inclusion is what Pakistani hormonal medicine has consistently failed to provide.